Cardiovascular profile of loratadine
- 1 July 1999
- journal article
- review article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 29 (S3) , 197-199
- https://doi.org/10.1046/j.1365-2222.1999.0290s3197.x
Abstract
The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre‐existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.Keywords
This publication has 10 references indexed in Scilit:
- Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation AntihistaminesMolecular Pharmacology, 1998
- Interactions of the Nonsedating Antihistamine Loratadine with a Kv1.5-Type Potassium Channel Cloned from Human HeartMolecular Pharmacology, 1997
- Comparative Effects of Loratadine and Terfenadine on Cardiac K+ ChannelsJournal of Cardiovascular Pharmacology, 1997
- HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine TerfenadineCirculation, 1996
- Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizoleFEBS Letters, 1996
- Cardiac Actions of AntihistaminesAnnual Review of Pharmacology and Toxicology, 1996
- Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea‐pigsClinical and Experimental Allergy, 1995
- Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations*Clinical Pharmacology & Therapeutics, 1995
- A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndromeCell, 1995
- Terfenadine-Ketoconazole InteractionJAMA, 1993